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In this issue of *Critical Care*, Cuthbertson and colleagues report \[[@B1]\] the views of 141 intensive care and infection control specialists from four countries on the potential utility, risks and research opportunities of selective digestive decontamination (SDD). Using structured interviews, a Delphi process, and a theoretical behavioural domains framework, they determined the extent of consensus and perceived importance of specific issues relating to SDD.

Respondents demonstrated substantial equipoise on risks and benefits of SDD combined with moderate agreement on concerns that SDD might contribute to antimicrobial resistance. There was uncertainty about the generalisability of SDD research to local context or to all patient groups, and moderately strong support for participating in a national randomised controlled trial of SDD despite a common view that SDD was not a high clinical priority, presumably related to the reported use of other strategies to minimise healthcare-associated infections and ventilator-associated pneumonia (VAP).

SDD is unique amongst intensive care interventions in having the largest and most consistent evidence base for benefit in terms of minimising secondary infections and reducing mortality. Since the initial publications by Stoutenbeek and van Saene in 1983 and 1984 \[[@B2],[@B3]\] describing SDD in mechanically ventilated trauma patients, there have been at least 65 randomised controlled trials and 12 meta-analyses involving around 15,000 patients. No other intervention approaches this weight of evidence, and yet expert opinion frequently disregards the technique. SDD was omitted from the first consensus statement of the Surviving Sepsis Campaign \[[@B4]\]; in the second iteration \[[@B5]\] SDD was considered but no recommendation made, since expert opinion was shown to be bimodal, demonstrated through the development of the GRADE Grid \[[@B6]\]. In the third iteration in 2012--2013 \[[@B7]\], SDD has achieved a level 2B recommendation (suggested use based on \'moderate evidence'). What are the reasons for this gap between evidence and uptake?

The main barrier to SDD relates to the perceived risk of antimicrobial resistance (or emergence of species not covered by the traditional regimen, such as Gram-positive bacteria) if SDD were to be widely adopted, with the spread of these organisms to the wider environment. The historical over-use of antimicrobials (intravenous and oral in humans, as growth promoters in animals) has led to calls for better antimicrobial stewardship, and doctors are now conditioned to minimise frequency and duration of prescriptions. Prolonged use of prophylactic antimicrobials therefore appears to run counter to this philosophy. In the current survey respondents tended to support the statements that SDD increases antimicrobial resistance and that research to date has not adequately addressed this issue. However, recent studies \[[@B8]-[@B12]\] do not support either position; in the two largest trials, rates of resistance were lower in the SDD group \[[@B8],[@B10]\]. Indeed, it is the conventional use of broad-spectrum intravenous antimicrobials that may promote the emergence of resistance by creating sub-lethal concentrations of antimicrobials in the gut, which then becomes a reservoir of pathogenic aerobic organisms in critically ill patients. This suggests the possibility that SDD may not only be unlikely to promote resistance, but also might actually prevent their emergence.

The second barrier relates to local perceptions of performance: the sense that SDD is not required because hospital acquired infections are already well-controlled. The majority of respondents agreed with the statement that \'Our VAP rates are low'. This may be the case if ICUs are regularly auditing their VAP rates. However, as we found in the Matching Michigan project \[[@B13]-[@B15]\], many ICUs were surprised to find that their performance in minimising blood stream infections from central venous catheters was not as good as they had expected.

The third barrier may be the availability of \'competing' non-antimicrobial interventions for preventing VAP in mechanically ventilated patients, often combined in \'VAP bundles'. SDD should be compared with these non-antimicrobial approaches to determine whether there is synergy, or whether the newer techniques can substitute for SDD.

The final barrier to SDD might be uncertainty about who should receive it, in what form and with which components. Originally promoted as a technique for preventing gut overgrowth with potentially pathogenic Gram-negative aerobes by preserving the normal colonic anaerobic flora \[[@B2]\], it gradually came to be seen primarily as a technique for preventing VAP from retrograde oropharyngeal spread of enteric organisms. The classical nosocomial Gram-negative pathogens of the 1980s were replaced in the 1990s and 2000s by resistant Gram-positives for which SDD was not specifically designed; in recent years multiply-resistant Gram-negatives have returned. This means that the SDD regimen must be adapted to local circumstance - for example, including enteral vancomycin or modifying the anti-Gram-negative components. Evolving concepts of the mechanism(s) of action of SDD now re-emphasise the gut as the primary reservoir of pathogenic organisms, and establishment of normal enteric flora as the main therapeutic aim \[[@B16],[@B17]\]. To this extent SDD and interventions directed at increasing splanchnic blood flow share the same conceptual framework of the gut as \'the largest undrained abscess in the body'.

One question that the survey did not directly ask is \'what evidence and effect size would encourage you to use SDD as a routine intervention in mechanically ventilated patients?' The answer to this is likely to include the absence of emergence of resistance over several years (at both the individual and environmental level) and improvements in survival to at least 1 year. It is clear that the research will need to compare SDD against non-antimicrobial interventions directed against VAP, and will need to take into account local microbial ecology. A multicentre cluster-randomised trial has been proposed \[[@B12]\]; this might usefully include a factorial design with blinding of the SDD component to explore potential synergies between interventions rather than a straight head-to-head comparison. Such a trial might finally allow us to move from practice based on \'gut instinct' to evidence-based medicine.
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